Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

Overview publication

TitleSunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
DateMarch 1st, 2024
Issue nameThe Lancet
Issue numberv403.10431 p1061-1070
DOI10.1016/s0140-6736(23)02554-0
AuthorsBaudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, Nölting S, de la Fouchardière C, Kienitz T, Deutschbein T, Zovato S, Amar L, Haissaguerre M, Timmers H, Niccoli P, Faggiano A, Angokai M, Lamartina L, Luca F, Cosentini D, Hahner S, Beuschlein F, Attard M, Texier M, Fassnacht M, DOCAO C, Drui D, Borson Chazot F, Chabre O, Vezzosi D, Castinetti F, Bertherat J, Libé R, Gimenez-Roqueplo AP, Favier J, Quinkler M, Strasburger C, Zopf K, Reincke M, Kroiss M, Remde H, Haaf M, Fuß CT, Dischinger U, Eisenhofer G, Pamporaki C & Van Berkel A
MTGsMTG1
Read Read publication